country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-187225

Copy Link Print Information

NCP07

NCP07 is a PROTAC degrader targeting the coactivator-binding site (CBS) of ERα. NCP07 induces the formation of the ERα-NCP07-VHL ternary complex and promotes ERα degradation via the ubiquitin-proteasome system. NCP07 induces apoptosis and cell cycle arrest in endocrine therapy-resistant breast cancer cells. NCP07 inhibits the proliferation of wild-type and ESR1-mutant breast cancer cells. NCP07 is applicable to breast cancer-related research.
(Pink: ERα Target protein ligand; Blue: VHL ligand (HY-112078); Black: linker (HY-N0067)).

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

分子式: C₅₈H₇₂N₈O₁₃S
分子量:1121.30

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

NCP07 構造式

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

NCP07 is a PROTAC degrader targeting the coactivator-binding site (CBS) of ERα. NCP07 induces the formation of the ERα-NCP07-VHL ternary complex and promotes ERα degradation via the ubiquitin-proteasome system. NCP07 induces apoptosis and cell cycle arrest in endocrine therapy-resistant breast cancer cells. NCP07 inhibits the proliferation of wild-type and ESR1-mutant breast cancer cells. NCP07 is applicable to breast cancer-related research^[1]. (Pink: ERα Target protein ligand; Blue: VHL ligand (HY-112078); Black: linker (HY-N0067)).

IC₅₀ & Target

^[1]

ERα

PROTACs アイソフォーム固有の製品をすべて表示 :

Estrogen Receptor/ERR アイソフォーム固有の製品をすべて表示 :

体外実験

Anti-cancerApoptosisCell Cycle Regulation

Anti-cancer

NCP07 potently inhibits the proliferation of wild-type MCF-7 breast cancer cells with an IC₅₀ of 0.25 μM; it potently inhibits the proliferation of endocrine-resistant LCC2 breast cancer cells with an IC₅₀ of 1.01 μM; and it potently inhibits the proliferation of ESR1-mutant MCF-7^EGFR, MCF-7^D538G and MCF-7^Y537S breast cancer cells, with IC₅₀ values ranging from 0.13 to 1.22 μM^[1].
NCP07 (5-10 μM; 24 h) selectively degrades ERα in wild-type MCF-7 breast cancer cells^[1].
NCP07 (1-10 μM; 24 h) selectively degrades ERα in endocrine-resistant LCC2 breast cancer cells in a concentration-dependent manner^[1].
NCP07 (1-10 μM; 12 h) selectively degrades ERα in a concentration-dependent manner in T47D breast cancer cells as well as ESR1-mutated MCF-7^EGFR, MCF-7^D538G and MCF-7^Y537S breast cancer cells^[1].
NCP07 (5 μM) induces ERα degradation in endocrine-resistant LCC2 breast cancer cells via specific binding to the ERα coactivator binding site (CBS); it can induce the formation of a stable ERα-NCP07-VHL ternary complex in endocrine therapy-resistant LCC2 breast cancer cells through specific binding to ERα CBS^[1].

Anti-cancer

Apoptosis

NCP07 (0.1-20 μM; 72 h) induces apoptosis in endocrine-resistant LCC2 breast cancer cells in a concentration-dependent manner^[1].
NCP07 (1-10 μM; 72 h) activates the apoptotic signaling pathway in endocrine-resistant LCC2 breast cancer cells, inducing caspase-3 activation and PARP cleavage^[1].

Anti-cancer

Cell Cycle Regulation

NCP07 (1-20 μM; 48 h) selectively induces G1-phase cell cycle arrest in endocrine-resistant LCC2 breast cancer cells in vitro in a concentration-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

wild-type MCF-7 breast cancer cells
Concentration:

5, 10 μM
Incubation Time:

24 h
Result:

Induced ~20% degradation of ERα at 5 μM.
Induced ~75% degradation of ERα at 10 μM.

Western Blot Analysis^[1]

Cell Line:

endocrine-resistant LCC2 breast cancer cells
Concentration:

1, 5, 10 μM
Incubation Time:

24 h
Result:

Induced degradation of ERα.

Western Blot Analysis^[1]

Cell Line:

ESR1-mutated breast cancer cells (MCF-7^EGFR, MCF-7^D538G, MCF-7^Y537S) and T47D breast cancer cells
Concentration:

1, 5, 10 μM
Incubation Time:

12 h
Result:

Induced graded ERα degradation in four cell strains: T47D (60/80/90%), MCF-7^EGFR (50/70/80%), MCF-7^D538G (30/50/70%), MCF-7^Y537S (20/40/60%) at 1, 5, 10 μM.

Immunofluorescence^[1]

Cell Line:

endocrine-resistant LCC2 breast cancer cells
Concentration:

10 μM (NCP07); 5 μM (E2 co-incubated); 3 μM (KP1490 co-incubated)
Incubation Time:

12 h
Result:

Induced significant co-localization of ERα and VHL (orange-yellow merged fluorescence) in the nucleus.
Co-incubation with KP1490 inhibited ERα-VHL co-localization.
Co-incubation with E2 did not inhibit ERα-VHL co-localization.

Apoptosis Analysis^[1]

Cell Line:

endocrine-resistant LCC2 breast cancer cells
Concentration:

0.1, 1, 10, 20 μM
Incubation Time:

72 h
Result:

Induced concentration-dependent apoptosis in LCC2 cells.

Western Blot Analysis^[1]

Cell Line:

endocrine-resistant LCC2 breast cancer cells
Concentration:

1, 5 μM (PRAP)
1, 5, 10 μM (Caspase-3)
5 μM (cleaved forms)
Incubation Time:

72 h
Result:

Induced concentration-dependent reduction in full-length PARP protein levels.
Induced concentration-dependent reduction in full-length caspase-3 protein levels.
Induced corresponding concentration-dependent increases in cleaved-PARP levels.
Induced corresponding concentration-dependent increases in cleaved-caspase-3 levels.

Cell Cycle Analysis^[1]

Cell Line:

wild-type MCF-7 and endocrine-resistant LCC2 breast cancer cells
Concentration:

1, 10, 20 μM
Incubation Time:

48 h
Result:

Showed no significant effect on cell cycle distribution in MCF-7 cells.
Induced concentration-dependent G1 phase arrest in LCC2 cells.
At 20 μM, 87.80% of LCC2 cells were in G1 phase.

体内実験

NCP07 (500 mg/kg; single administration) exhibits favorable in vivo safety, with no adverse reactions or body weight changes detected^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

化学情報

分子量 1121.30
分子式 C₅₈H₇₂N₈O₁₃S
SMILES

C[C@@H](C1=CC=C(C2=C(C)N=CS2)C=C1)NC([C@H](C[C@@H](O)C3)N3C([C@H](C(C)(C)C)NC(CCCNC(C(C=C4)=CC(OCC(C)C)=C4NC(C(C=C5)=CC(OCC(C)C)=C5NC(C6=CC(OCCO)=C([N+]([O-])=O)C=C6)=O)=O)=O)=O)=O)=O
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Liang J, et al. NCP07: A potent ERα CBS-targeted degrader with dual-action against ESR1 mutations in breast cancer. European journal of medicinal chemistry. 2026 Jun 30;317:119113. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ

Amount: USD 0.00

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
純度とドキュメンテーション
参考文献

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

NCP07

PROTACs アイソフォーム固有の製品をすべて表示

Estrogen Receptor/ERR アイソフォーム固有の製品をすべて表示

生物活性

製品説明

IC50 & Target

体外実験

体内実験

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

NCP07 関連分類

HY-187225 関連分類

Bioz

Keywords

最近チェックした製品

IC₅₀ & Target